POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

Abstract

This disclosure provides an engineered polynucleotide that interacts with a pre-mRNA and a spliceosome to regulate gene expression. The engineered polynucleotide may have stem-loop structure that recruits the spliceosome and targeting sequences that are complementary to a target sequence at an exon-intron splice junction and may include nucleotides with 2′ modifications and phosphorothioate linkages. The engineered polynucleotide can be administered to a subject to treat a cancer.

CPC Classifications